37860-86-9

Upstream product

• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 107-91-5 cyanoacetic acid amide 
• 39621-09-5 2,6-dihydroxy-4-phenyl-3-cyano-pyridine 
• 98-86-2 acetophenone 
• 54441-64-4 butyl 3-oxo-3-phenylpropanoate 

Downstream Products

• 66662-88-2 2-chloro-6-morpholino-4-phenylnicotinonitrile 
• 1299492-98-0 2-chloro-6-(2-(dimethylamino)ethylamino)-4-phenylnicotinonitrile 
• 1299492-82-2 3-amino-6-(2-(dimethylamino)ethylamino)-4-phenylthieno[2,3-b]pyridine-2-carboxylic acid (1-methyl-1H-pyrrol-2-yl-methylene)hydrazide 
• 1299493-10-9 3-amino-6-(2-(dimethylamino)ethylamino)-4-phenylthieno[2,3-b]pyridine-2-carboxylic acid hydrazide 
• 1299493-05-2 3-amino-6-(2-(dimethylamino)ethylamino)-4-phenylthieno[2,3-b]pyridine-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

The Guareschi-Thorpe Cyclization Revisited - An Efficient Synthesis of Substituted 2,6-Dihydroxypyridines and 2,6-Dichloropyridines

DBU as base is key in a practical modified Guareschi-Thorpe cyclization of β-keto esters and 2-cyanoacetamide to allow the synthesis of substituted pyridones in good to excellent yields. The chlorination of DBU salts of pyridones with POCl 3 in the presence of a quaternary ammonium salt under standard atmospheric reflux conditions as opposed to the typical pressure equipment led to high yields of substituted 2,6-dichloropyridines.

Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2AReceptor

In this study, we determined the crystal structure of an engineered human adenosine A2A receptor bound to a partial agonist and compared it to structures cocrystallized with either a full agonist or an antagonist/inverse agonist. The interaction between the partial agonist, belonging to a class of dicyanopyridines, and amino acids in the ligand binding pocket inspired us to develop a small library of derivatives and assess their affinity in radioligand binding studies and potency and intrinsic activity in a functional, label-free, intact cell assay. It appeared that some of the derivatives retained the partial agonist profile, whereas other ligands turned into inverse agonists. We rationalized this remarkable behavior with additional computational docking studies.

The guareschi pyridine scaffold as a valuable platform for the identification of selective PI3K inhibitors

A novel series of 4-aryl-3-cyano-2-(3-hydroxyphenyl)-6-morpholino-pyridines have been designed as potential phosphatidylinositol-3-kinase (PI3K) inhibitors. The compounds have been synthesized using the Guareschi reaction to prepare the key 4-aryl- 3-cyano-2,6-dihydroxypyridine intermediate. A different selectivity according to the nature of the aryl group has been observed. Compound 9b is a selective inhibitor against the PI3Kα isoform, maintaining a good inhibitory activity. Docking studies were also performed in order to rationalize its profile of selectivity.

Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors

Among the recently investigated targets for cancer therapy is the c-Src non-receptor tyrosine kinase. Indeed research around deregulated activity of this enzyme has proven its role in tumor progression, while the beneficial effects of c-Src inhibitors in several pathological models has also been demonstrated. We report here the preparation and pharmacological profile of a novel series of c-Src inhibitors that was elaborated around a 3-amino-thieno[2,3-b]pyridine discovered during an HTS campaign. c-Src enzyme inhibition and c-Src inhibition were investigated in a series of related compounds derived from the initial hit. Molecular modeling as well as X-ray studies on one active compound allowed us to hypothesize on ligand orientation and interactions within the ATP hydrophobic pocket. Design and synthesis of structural analogs then led to new ligands possessing quite efficient enzymatic and c-Src inhibition. The structure-activity elements disclosed in this study shed light on the role played by substituents on the thienopyridine ring as well as the impact of other aromatic moieties in the molecule when interacting with the enzyme.

CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE

A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.

3-Amino-4-phenyl-6-piperidino-1H-pyrazolo[3,4-b]-pyridines and salts thereof

Compounds of the formula STR1 wherein R1 is unsubstituted, mono-substituted or di-substituted piperidino, where the substituents are selected from the group consisting of methyl, hydroxymethyl, hydroxyl, phenyl and benzyl; R2 is hydr

3-Amino-4-phenyl-1H-pyrazolo[3,4-b]pyridines and salts thereof

Compounds of the formula STR1 wherein R1 is mono- or di-substituted amino, where the substituents are selected from the group consisting of alkyl of 1 to 6 carbon atoms, cyclohexyl, allyl and benzyl; unsubstituted, mono-substituted or di-substi